ATAI Life Sciences announces close of $24 million convertible note financing round and welcomes Jason Camm of Thiel Capital to Board of Directors
Summary
LONDON and NEW YORK, April 23, 2020 /PRNewswire/ -- ATAI Life Sciences , a global biotechnology company builder founded by Christian Angermayer that envisions an end to mental illnesses, today announced the close of a $24 million convertible note financing round. Despite market turmoil caused by the COVID-19 pandemic, the round saw strong support from both new and existing investors.Several globally renowned investors like Peter Thiel as well as Steve Jurvetson and Maryanna Saenko of Future Ventures join ATAIs numerous other reputable backers like Michael Novogratz Galaxy Digital, Thor Bjorgolfsson, Efrem Kamen, and ATAI founder Christian Angermayers Apeiron Investment Group, all of whom also purchased additional notes in the round. "We are thrilled to have partners like Peter Thiel and Future Ventures with us for the next phase of our journey," said Christian Angermayer, Founder of ATAI. "ATAI is recognized as the worlds leading mental health biotech company, leveraging a decentralized, tech- and data-driven platform that combines an emphasis on psychedelic compounds with non-psychedelics and artificial intelligence. ATAIs portfolio currently includes: psilocybin for treatment resistant depression; ibogaine for opioid use disorder; arketamine for treatment resistant depression; deuterated etifoxine for anxiety; and a company designing next-generation psychedelic medicines using computational biophysics.Additionally, Jason Camm, Managing Director and Chief Medical Officer at Thiel Capital, has joined ATAIs Board of Directors, effective immediately.